Scanning ultrasound-mediated memory and functional improvements do not require amyloid-β reduction.
Gerhard LeinengaXuan Vinh ToLiviu-Gabriel BodeaJumana YousefGina Richter-StrettonTishila PalliyaguruAntony ChicoteauLaura DagleyFatima NasrallahJürgen GötzPublished in: Molecular psychiatry (2024)
A prevalent view in treating age-dependent disorders including Alzheimer's disease (AD) is that the underlying amyloid plaque pathology must be targeted for cognitive improvements. In contrast, we report here that repeated scanning ultrasound (SUS) treatment at 1 MHz frequency can ameliorate memory deficits in the APP23 mouse model of AD without reducing amyloid-β (Aβ) burden. Different from previous studies that had shown Aβ clearance as a consequence of blood-brain barrier (BBB) opening, here, the BBB was not opened as no microbubbles were used. Quantitative SWATH proteomics and functional magnetic resonance imaging revealed that ultrasound induced long-lasting functional changes that correlate with the improvement in memory. Intriguingly, the treatment was more effective at a higher frequency (1 MHz) than at a frequency within the range currently explored in clinical trials in AD patients (286 kHz). Together, our data suggest frequency-dependent bio-effects of ultrasound and a dissociation of cognitive improvement and Aβ clearance, with important implications for the design of trials for AD therapies.
Keyphrases
- blood brain barrier
- magnetic resonance imaging
- clinical trial
- mouse model
- working memory
- high resolution
- end stage renal disease
- contrast enhanced
- newly diagnosed
- chronic kidney disease
- ultrasound guided
- ejection fraction
- computed tomography
- magnetic resonance
- peritoneal dialysis
- traumatic brain injury
- high frequency
- randomized controlled trial
- mass spectrometry
- cerebral ischemia
- high glucose
- brain injury
- deep learning
- drug induced
- phase ii
- case control
- data analysis
- oxidative stress